Anisomycin protects against sepsis by attenuating IκB kinase-dependent NF-κB activation and inflammatory gene...

Area of Science:

• Immunology
• Pharmacology
• Molecular Biology

Background:

• Anisomycin is an antibiotic and anticancer drug that inhibits protein synthesis.
• The precise molecular targets and mechanisms of anisomycin in macrophages remain unclear.
• Acute inflammation and sepsis involve complex cellular signaling pathways.

Purpose of the Study:

• To investigate the anti-inflammatory effects of anisomycin in macrophages.
• To elucidate the mechanism of action of anisomycin in sepsis models.
• To evaluate anisomycin as a potential therapeutic agent for acute inflammation and sepsis.

Main Methods:

• In vivo and in vitro experiments using cecal ligation and puncture (CLP) and lipopolysaccharide (LPS) models.
• Assessment of macrophage mortality rates and gene expression of inflammatory mediators.
• Analysis of nitric oxide and cytokine production.
• Evaluation of nuclear factor-kappa B (NF-κB) pathway activation, including kinase phosphorylation, IκBα degradation, and NF-κB p65 subunit translocation.

Main Results:

• Anisomycin decreased mortality in CLP- and LPS-induced acute sepsis models.
• Anisomycin reduced the gene expression of inducible nitric oxide synthase, tumor necrosis factor-α, and interleukin-1β.
• Anisomycin suppressed nitric oxide and proinflammatory cytokine production in LPS-treated macrophages.
• Anisomycin attenuated NF-κB activation by inhibiting upstream kinases and IκBα degradation, preventing NF-κB p65 nuclear translocation.

Conclusions:

• Anisomycin exhibits significant anti-inflammatory effects in sepsis models.
• The mechanism involves the inhibition of NF-κB signaling pathway activation.
• Anisomycin demonstrates potential as a therapeutic candidate for treating sepsis and related inflammatory conditions.